One was a cohort of 105 patients with MEN1 from the US, which observed that 94% [16/17] of patients with metastatic tumors had type O blood compared to 74% [32/43] of patients with a benign tumor who had non-O blood type [15]. This evidence concerns the gene MEN1 and metastatic neoplasm.